<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01544023</url>
  </required_header>
  <id_info>
    <org_study_id>TL001</org_study_id>
    <nct_id>NCT01544023</nct_id>
  </id_info>
  <brief_title>TiLoop® Bra for Breast Reconstruction</brief_title>
  <official_title>Multicenter Observational Study of Implant Based Breast Reconstruction Using a Titanium-coated Polypropylene Mesh</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rostock</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rostock</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A new approach for single stage implant based breast reconstruction (BR) is the use of a
      titanium-coated polypropylene mesh (TCPM) as an alternative to acellular dermal matrix (ADM).
      These TCPM have a good biocompatibility and can be used in a similar way as ADM. This study
      addresses indications, limitations and complications of TCPM in implant based breast
      reconstruction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An alternative to ADM is the usage of a titanium-coated polypropylene mesh (TCPM=TiLOOP(R)
      Bra), which is approved for breast reconstruction in Europe. The surgical approach is
      identical in comparison to ADM reconstruction and has been described previously. This
      titanium coated lightweight mesh consists of a monofilament structure and was initially
      invented for hernia repair which has a good biocompatibility. Observed cellular reactions
      like proliferation and apoptosis were at the lowest level when using this lightweight TCPM
      compared to not titanium-coated meshes (pure polypropylene (PP), pure lightweight PP mesh or
      PP mesh incorporating resorbable polyglactic acid). Histopathological analysis of an
      intraoperative sample of a TCPM after expander/implant BR demonstrated a well incorporated
      mesh with only weak inflammatory reactions. Preliminary data of in-vitro investigations at
      the investigators institute confirms the good biocompatibility of this TCPM in distinctive
      breast tissues (fibroblasts, fat cells, muscle cells) Although meshes are used in a large
      scale there are no sufficient clinical data regarding safety and outcome. In this multicenter
      study the investigators are able to investigate a large cohort of patients undergoing implant
      based breast reconstruction using a TCPM.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Participants Who Received TiLOOP Mesh Reconstruction</measure>
    <time_frame>1 month</time_frame>
    <description>Primary study endpoint was the identification of patient- and surgical factors predictive of adverse outcome and to develop recommendations for patients eligible for implant based breast reconstruction (IBBR) using TCPM.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complication Rate</measure>
    <time_frame>2 years</time_frame>
    <description>Secondary study outcome was the prevalence of complications.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">207</enrollment>
  <condition>Patient and Surgical Related Risk Factors for Complications</condition>
  <arm_group>
    <arm_group_label>Breast Reconstruction with TilOOP</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients eligible for immediate or secondary implant based breast reconstruction.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for immediate or secondary implant based breast reconstruction

        Exclusion Criteria:

          -  age &lt; 18 years
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Max Dieterich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rostock</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernd Gerber, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Rostock</affiliation>
  </overall_official>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2012</study_first_posted>
  <results_first_submitted>November 30, 2015</results_first_submitted>
  <results_first_submitted_qc>December 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 16, 2017</results_first_posted>
  <last_update_submitted>December 26, 2016</last_update_submitted>
  <last_update_submitted_qc>December 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rostock</investigator_affiliation>
    <investigator_full_name>Max Dieterich</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <keyword>breast reconstruction</keyword>
  <keyword>mesh</keyword>
  <keyword>implant reconstruction</keyword>
  <keyword>acellular dermal matrix</keyword>
  <keyword>titanized polypropylene mesh</keyword>
  <keyword>TiLOOP Bra</keyword>
  <keyword>TiLOOP</keyword>
  <keyword>implant based breast reconstruction</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TiLOOP</title>
          <description>Patients with immediate or delayed-immediate heterologous BR who underwent skin-sparing (SSM) or nipple-sparing mastectomy (NSM) with silicone implants in combination with TiLOOP&quot; Bra (pfm medical, Cologne, Germany) were included.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="207">retrospective</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TiLOOP</title>
          <description>Patients with immediate or delayed-immediate heterologous BR who underwent skin-sparing (SSM) or nipple-sparing mastectomy (NSM) with silicone implants in combination with TiLOOP&quot; Bra (pfm medical, Cologne, Germany) were included.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="207"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants Who Received TiLOOP Mesh Reconstruction</title>
        <description>Primary study endpoint was the identification of patient- and surgical factors predictive of adverse outcome and to develop recommendations for patients eligible for implant based breast reconstruction (IBBR) using TCPM.</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TiLOOP</title>
            <description>Patients with immediate or delayed-immediate heterologous BR who underwent skin-sparing (SSM) or nipple-sparing mastectomy (NSM) with silicone implants in combination with TiLOOP&quot; Bra (pfm medical, Cologne, Germany) were included.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Received TiLOOP Mesh Reconstruction</title>
          <description>Primary study endpoint was the identification of patient- and surgical factors predictive of adverse outcome and to develop recommendations for patients eligible for implant based breast reconstruction (IBBR) using TCPM.</description>
          <units>Patients with TiLOOP mesh reconstruction</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complication Rate</title>
        <description>Secondary study outcome was the prevalence of complications.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TiLOOP</title>
            <description>Patients with immediate or delayed-immediate heterologous BR who underwent skin-sparing (SSM) or nipple-sparing mastectomy (NSM) with silicone implants in combination with TiLOOP&quot; Bra (pfm medical, Cologne, Germany) were included.</description>
          </group>
        </group_list>
        <measure>
          <title>Complication Rate</title>
          <description>Secondary study outcome was the prevalence of complications.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major Complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor Complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Retrospective chart analysis. With Follow up up to 2 years</time_frame>
      <desc>Adverse Events were not collected/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>TiLOOP</title>
          <description>Patients with immediate or delayed-immediate heterologous BR who underwent skin-sparing (SSM) or nipple-sparing mastectomy (NSM) with silicone implants in combination with TiLOOP&quot; Bra (pfm medical, Cologne, Germany) were included.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Max Dieterich</name_or_title>
      <organization>University of Rostock, Klinikum Südstadt der Hansestadt Rostock, Frauenklinik</organization>
      <phone>+4938144016145</phone>
      <email>max.dieterich@uni-rostock.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

